EP1034173B1 - Verfahren zur herstellung von 8-methoxy-chinoloncarbonsäuren - Google Patents

Verfahren zur herstellung von 8-methoxy-chinoloncarbonsäuren Download PDF

Info

Publication number: EP1034173B1
Authority: EP; European Patent Office
Prior art keywords: process according; solvent; formula; reaction; preparing
Prior art date: 1997-11-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

EP98959874A

Other languages

German (de)

English (en)

French (fr)

Other versions

EP1034173A2 (de

Inventor

Reinhold Gehring

Klaus Mohrs

Werner Heilmann

Herbert Diehl

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bayer Intellectual Property GmbH

Original Assignee

Bayer Healthcare AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-11-24

Filing date

1998-11-12

Publication date

2005-04-27

1998-11-12 Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG

1998-11-12 Priority to DK98959874T priority Critical patent/DK1034173T3/da

1998-11-12 Priority to SI9830772T priority patent/SI1034173T1/xx

2000-09-13 Publication of EP1034173A2 publication Critical patent/EP1034173A2/de

2005-04-27 Application granted granted Critical

2005-04-27 Publication of EP1034173B1 publication Critical patent/EP1034173B1/de

2018-11-12 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Definitions

the invention relates to a process for the preparation of 8-methoxy-quinolonecarboxylic acids.
8-methoxy-quinolonecarboxylic acids provide antibiotics with high antibacterial activity against gram-negative and gram-positive bacteria.
the antibiotics 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7- (3-methyl-1-piperazinyl) -4-oxo-3-quinolinecarboxylic acid (INN, gatifloxacin, EP-A-230 295) and 1-cyclopropyl-7- [S, S] -2,8-diazabicyclo [4.3.0] non-8-yl) -6-fluoro-1,4- dihydro-8-methoxy-4-oxo-3-quinolonecarboxylic acid hydrochloride monohydrate (Bay 12-8039, EP-A-0 350,733) in the 8-position on a methoxy group.
Such antibacterially highly effective quinolonecarboxylic acids usually have one heteromonocyclic or heteropolycyclic amine radical in the 7-position of the Quinolonecarboxylic acid on This cyclic amine radical is generally through nucleophilic substitution of the corresponding 7-halo-quinolonecarboxylic acid with the each amine produced.
the introduction of the 8-alkoxy group can in principle before Introduction of the cyclic amine radical in the 7-position or carried out thereafter.
EP-A-0 350 733 describes the preparation of the racemic betaine of the above Bay 12-8039, starting from the corresponding 8-methoxy compound, the preparation of which is described in EP-A-0 241 206 (preparation 6) nucleophilic substitution with the corresponding racemic amine.
Analog is the Preparation of the enantiomerically pure betaine of Bay 12-8039, starting from the 8-methoxy compound by nucleophilic substitution with the enantiopure Amin in EP-A-0 550 903 (Example 19).
preparation route requires a complicated isolation and cleaning by Column chromatography, which is undesirable for the industrial scale. The latter The path is also taken in EP-A-0 591 808 (Example Z 19).
Another way of introducing an 8-alkoxy substituent into the 7-amine substituted Quinolonecarboxylic acids consists in the 8-alkoxy substitution, after the cyclic amine substituent at the 7-position from the corresponding starting 7,8-dihalo compound had received.
EP-A-0 106 489 describes the route of 8-methoxy substitution after introduction of the heterocyclyl substituent in the 7-position by reacting the corresponding 8-fluoro compound in methanol in the presence of potassium tert-butoxide.
the there reaction with the 7- [2 - [(methylamino) methyl] -4-thiazole] compound requires 24 hours under reflux and is therefore in the implementation technical scale unsuitable.
certain quinolonecarboxylic acids, such as Bay 12-8039 described above in this way can not be prepared because under the conditions of the reaction below Reflux for 24 hours no reaction takes place.
the object of the present invention is thus a method to develop for the preparation of 8-methoxy derivatives of quinolonecarboxylic acids, the short reaction times, working under atmospheric pressure a complete Implementation and easy workup of the reaction mixture allows, too develop.
8-methoxy-quinolonecarboxylic acid derivatives in a process which satisfies the above requirements by reacting the corresponding 8-halo-quinolonecarboxylic acid derivatives with (C 1 -C 3 ) -alkanols or benzyl alcohol and sodium or potassium tert.-butylate or sodium or potassium tert.amylate in the presence of aliphatic or cycloaliphatic ethers having 4 to 6 carbon atoms as solvent.
the group forms a mono- or bicyclic heterocycle which may optionally contain in all ring parts further nitrogen, oxygen or sulfur heteroatoms and may optionally be substituted.
the ring members R 'and R may be the same or different ring constituents therein.”
Such mono- or bicyclic amine residues in the 7-position of the quinolonecarboxylic acid base are basically known in the field of quinolonecarboxylic acid antibiotics.
EP-A-0 523 512 EP-A-0 230 295, EP-A-0 705 828, EP-A-0 589 318, EP-A-0 357 047, EP-A-0 588 166, GB-A-2 289 674, WO 92/09 579, JP-03-007 283, EP-A-0 241 206, EP-A-0 342 675, WO 93/22 308 and EP-A-0 350 733.
the aliphatic or cycloaliphatic ether having 4 to 6 carbon atoms is preferably selected from dimethoxyethane, dioxane and tetrahydrofuran.
Hal is preferably fluorine in the process according to the invention.
the (C 1 -C 3 ) -alkanol is preferably methanol, ie the process is preferably used for the preparation of the 8-methoxy compound.
M is preferably potassium, i. the reaction is preferably carried out with potassium tert-butylate or amylate, more preferably potassium tert-butoxide.
1 equivalent of the compound of the formula are preferably 1 to 3, more preferably 1.1 to 1.3 equivalents of the (C 1 -C 3 ) -alkanol or of the benzyl alcohol, and 2 to 3, preferably 2.1 to 2.3 equivalents of the compound of the formula used.
the reaction is preferably between 20 ° C and the boiling temperature of the solvent carried out at atmospheric pressure.
the process is preferably in dimethoxyethane, dioxane, tetrahydrofuran or Mixtures of it carried out.
the (C 1 -C 3 ) -alkanol is methanol, ie the 8-methoxy compound is prepared (Bay 12-8039).
M is preferably potassium.
Preferred are based on 1 equivalent of the compound of the formula 1 to 3, particularly preferably 1.1 to 1.3 equivalents of the (C 1 -C 3 ) -alkanol or of the benzyl alcohol, and 2 to 3, preferably 2.1 to 2.3 equivalents of the compound of the formula used.
the process is preferably between 20 ° C and the boiling temperature of the solvent carried out at atmospheric pressure.
the process of the present invention is particularly suitable for the production of
the compound of the formula are preferably 1 to 3, more preferably 1.1 to 1.3 equivalents of methanol and 2 to 3, preferably 2.1 to 2.3 equivalents of potassium tert-butoxide used and the reaction is between 20 ° C and the boiling point of Solvent carried out at atmospheric pressure.
a particular advantage of the process according to the invention is that the preparation of pharmaceutically acceptable salts of the compounds described above, for example the hydrochlorides, particularly easily by addition of the resulting reaction mixture with dilute hydrochloric acid or addition of the reaction mixture to dilute hydrochloric acid and isolation of the salt, preferably the hydrochloride, by filtration, succeed.
This immediate preparation of the hydrochloride is preferably used to prepare the compound of the following formula:
the above-described compound (Bay 12-8039, hydrochloride) can surprisingly be isolated in high purity by recrystallization from water or a water / (C 1 -C 3 ) -alkanol mixture.
the purity of the compound thus obtained is already sufficient for many pharmaceutical applications.
the recrystallization preferably takes place from water or a water / ethanol mixture.
hydrochloride described above can also surprisingly in a simple manner on an industrial scale, a particularly stable mono-hydrate of the formula with a specific crystal structure, as described in DE-A-1 95 46 249 (corresponding to EP-A-0 780 390), by drying the resulting product at 40 to 60 ° C and 80 to 120 mbar. This drying is particularly preferably carried out at about 50 ° C. and about 100 mbar.
(C 1 -C 3 ) -alkyl or -alkyl radicals in the above definitions generally represents, for example, methyl, ethyl, propyl, isopropyl.
(C 1 -C 3 ) -alkyl and the (C 1 -C 3 ) -alkyl radical in the corresponding aliphatic radicals represent methyl.
the product can be purified analogously to Example 1 and into the monohydrate be transferred.
the moist solid (108.2 g) is suspended in 385 ml of water for 30 minutes at 20 stirred to 25 ° C, filtered off with suction and washed twice with 38 ml of water (bad Absorbency).
the precipitated crystals are filtered off with suction and washed twice with 10 ml of methanol.
the process according to the invention thus offers, in particular, on an industrial scale enormous advantages in yield, reaction time and work-up.

Landscapes

Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Agronomy & Crop Science (AREA)
Dentistry (AREA)
Wood Science & Technology (AREA)
Plant Pathology (AREA)
Zoology (AREA)
Pest Control & Pesticides (AREA)
Environmental Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Quinoline Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

EP98959874A 1997-11-24 1998-11-12 Verfahren zur herstellung von 8-methoxy-chinoloncarbonsäuren Expired - Lifetime EP1034173B1 (de)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
DK98959874T DK1034173T3 (da)	1997-11-24	1998-11-12	Fremgangsmåde til fremstilling af 8-methoxy-quinoloncarboxylsyrer
SI9830772T SI1034173T1 (en)	1997-11-24	1998-11-12	Method for producing 8-methoxy-quinoline carboxylic acids

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE19751948		1997-11-24
DE19751948A DE19751948A1 (de)	1997-11-24	1997-11-24	Verfahren zur Herstellung von 8-Methoxy-Chinoloncarbonsäuren
PCT/EP1998/007237 WO1999026940A2 (de)	1997-11-24	1998-11-12	Verfahren zur herstellung von 8-methoxy-chinoloncarbonsäuren

Publications (2)

Publication Number	Publication Date
EP1034173A2 EP1034173A2 (de)	2000-09-13
EP1034173B1 true EP1034173B1 (de)	2005-04-27

Family

ID=7849617

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP98959874A Expired - Lifetime EP1034173B1 (de)	1997-11-24	1998-11-12	Verfahren zur herstellung von 8-methoxy-chinoloncarbonsäuren

Country Status (41)

Country	Link
US (2)	US6897315B2 (ko)
EP (1)	EP1034173B1 (ko)
JP (1)	JP4445667B2 (ko)
KR (1)	KR100589549B1 (ko)
CN (2)	CN1151151C (ko)
AR (1)	AR016694A1 (ko)
AT (1)	ATE294169T1 (ko)
AU (1)	AU732977B2 (ko)
BG (1)	BG64532B1 (ko)
BR (1)	BRPI9814894B8 (ko)
CA (2)	CA2711645C (ko)
CO (1)	CO5011069A1 (ko)
CU (1)	CU22953A3 (ko)
CZ (1)	CZ297212B6 (ko)
DE (2)	DE19751948A1 (ko)
DK (1)	DK1034173T3 (ko)
EE (1)	EE04281B1 (ko)
ES (1)	ES2241185T3 (ko)
HK (2)	HK1034080A1 (ko)
HN (1)	HN1998000179A (ko)
HR (1)	HRP20000332B1 (ko)
HU (1)	HU228337B1 (ko)
ID (1)	ID26840A (ko)
IL (1)	IL135866A0 (ko)
IN (1)	IN189753B (ko)
MY (1)	MY129324A (ko)
NO (1)	NO315748B1 (ko)
NZ (1)	NZ504657A (ko)
PE (1)	PE20000007A1 (ko)
PL (1)	PL192461B1 (ko)
PT (1)	PT1034173E (ko)
RU (1)	RU2219175C2 (ko)
SI (1)	SI1034173T1 (ko)
SK (1)	SK285492B6 (ko)
SV (1)	SV1998000139A (ko)
TR (1)	TR200001472T2 (ko)
TW (1)	TW513427B (ko)
UA (1)	UA56286C2 (ko)
UY (1)	UY25265A1 (ko)
WO (1)	WO1999026940A2 (ko)
ZA (1)	ZA9810669B (ko)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6608078B2 (en)	2000-05-08	2003-08-19	Wockhardt Limited	Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment
US7098219B2 (en)	2000-08-01	2006-08-29	Wockhart Limited	Inhibitors of cellular efflux pumps of microbes
US6964966B2 (en)	2001-04-25	2005-11-15	Wockhardt Limited	Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
US6878713B2 (en)	2001-04-25	2005-04-12	Wockhardt Limited	Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
WO2003099815A1 (en)	2002-05-28	2003-12-04	Wockhardt Limited	Crystalline fluoroquinolone arginine salt form
WO2004091619A1 (en) *	2003-04-09	2004-10-28	Dr. Reddy's Laboratories Limited	A crystalline form iii of anhydrous moxifloxacin hydrochloride and a process for preparation thereof
EP1651630A1 (en) *	2003-08-05	2006-05-03	Matrix Laboratories Ltd	An improved process for the preparation of moxifloxacin hydrochloride
JP5255183B2 (ja)	2003-09-04	2013-08-07	ウォックハートリミテッド	ベンゾキノリジン−２−カルボン酸アルギニン塩四水和物
ITMI20032259A1 (it) *	2003-11-20	2005-05-21	Chemi Spa	Nuovo polimorfo dell'acido 1-ciclopropil-7-(s,s-2,8-diazabciclo-4.3.0-non-8-il)-6-fluoro-1,4-diidro-8-metossi-4-oxo-chinolin carbossilico cloridrato e metodi per la sua preparazione
US7759362B2 (en) *	2004-04-21	2010-07-20	Institut Of Medicinal Biotechnology Chinese Academy Of Medical Sciences	Quinolonecarboxylic acid compounds, preparation methods and pharmaceutical uses thereof
WO2006134491A2 (en) *	2005-06-14	2006-12-21	Aurobindo Pharma Limited	New crystalline form of moxifloxacin hydrochloride and process for its preparation
ES2311391B1 (es) *	2007-02-07	2009-12-22	Quimica Sintetica, S.A.	Forma cristalina de moxifloxacino base.
EP2154137A1 (en)	2008-08-04	2010-02-17	Chemo Ibérica, S.A.	Crystalline form of moxifloxacin base
IT1393337B1 (it)	2009-03-06	2012-04-20	Italiana Sint Spa	Sintesi di (4as, 7as)-ottaidro-1h-pirrolo[3,4-b]piridina
IT1398952B1 (it) *	2010-03-19	2013-03-28	F S I Fabbrica Italiana Sint	Processo di preparazione della moxifloxacina e suoi sali
CN102030751B (zh) *	2010-12-01	2012-11-21	上虞京新药业有限公司	一种盐酸莫西沙星的结晶工艺
CN104370906A (zh) *	2014-11-17	2015-02-25	安徽美诺华药物化学有限公司	氟喹诺酮衍生物的制备方法
CN104370907A (zh) *	2014-11-17	2015-02-25	安徽美诺华药物化学有限公司	喹诺酮衍生物的制备方法
CN104447742A (zh) *	2014-11-17	2015-03-25	安徽美诺华药物化学有限公司	一种喹诺酮衍生物的制备方法
CN104447741A (zh) *	2014-11-17	2015-03-25	安徽美诺华药物化学有限公司	一种氟喹诺酮衍生物的制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT77267B (en) *	1982-09-07	1986-03-21	Lilly Co Eli	Improved process for preparing novel octahydrobenz <f> isoquinolines or compounds relating thereto
IE55898B1 (en) *	1982-09-09	1991-02-14	Warner Lambert Co	Antibacterial agents
JPH089597B2 (ja) *	1986-01-21	1996-01-31	杏林製薬株式会社	選択毒性に優れた８‐アルコキシキノロンカルボン酸およびその塩並びにその製造方法
JPS62205060A (ja) *	1986-03-04	1987-09-09	Kyorin Pharmaceut Co Ltd	８位置換キノロンカルボン酸誘導体
FI871419A (fi) *	1986-03-31	1987-10-01	Sankyo Co	Kinolin-3-karboxylsyraderivat, deras framstaellning och anvaendning.
EP0342675B1 (en) *	1988-05-19	1995-01-25	Chugai Seiyaku Kabushiki Kaisha	Novel quinolonecarboxylic acid derivatives
DE3906365A1 (de)	1988-07-15	1990-01-18	Bayer Ag	7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
CA1336090C (en)	1988-08-31	1995-06-27	Isao Hayakawa	Spiro-substituted cyclic amines of quinolone derivatives
WO1990006305A1 (en)	1988-12-09	1990-06-14	Dainippon Pharmaceutical Co., Ltd.	Quinolonecarboxylic acid derivatives, process for their preparation and medicinal composition containing same
JP2761566B2 (ja)	1989-03-10	1998-06-04	吉富製薬株式会社	ピリドンカルボン酸化合物
WO1992009579A1 (en)	1990-11-30	1992-06-11	Yoshitomi Pharmaceutical Industries, Ltd.	Quinolonecarboxylic acid compound and its use
JPH05117238A (ja)	1991-10-23	1993-05-14	Chugai Pharmaceut Co Ltd	キノロンカルボン酸誘導体の製造方法及びその合成中間体
TW209865B (ko)	1992-01-10	1993-07-21	Bayer Ag
WO1993022308A1 (en)	1992-04-28	1993-11-11	Chugai Seiyaku Kabushiki Kaisha	Process for producing quinolonecarboxylic acid derivative
NO304832B1 (no) *	1992-05-27	1999-02-22	Ube Industries	Aminokinolonderivater samt middel mot HIV
DE4230804A1 (de)	1992-09-15	1994-03-17	Bayer Ag	7-Isoindolinyl-chinolon- und -naphthyridon-Derivate
DE4232172A1 (de)	1992-09-25	1994-03-31	Bayer Ag	7-(Aminomethyl-oxa-7-aza-bicyclo[3.3.0]oct-7-yl)chinolon- und Naphthyridoncarbonsäure-Derivate
DE4234078A1 (de) *	1992-10-09	1994-04-14	Bayer Ag	Chinoloncarbonsäuren
DE4234330A1 (de) *	1992-10-12	1994-04-14	Bayer Ag	Chinoloncarbonsäuren
EP0677522A4 (en) *	1992-12-28	1995-12-27	Yoshitomi Pharmaceutical	8-METHOXYQUINOLONECARBOXYLIC ACID DERIVATIVE.
CA2114981A1 (en) *	1993-02-09	1994-08-10	Kazumi Ogata	Quinolonecarboxylic acid derivatives
AU4272793A (en) *	1993-04-24	1994-11-21	Korea Research Institute Of Chemical Technology	Novel quinolone carboxylic acid derivatives and process for preparing the same
US5631266A (en) *	1993-04-26	1997-05-20	Korea Research Institute Of Chemical Technology	Quinolone carboxylic acid derivatives and process for preparing the same
KR950018003A (ko) *	1993-12-09	1995-07-22	스미스클라인 비참 피엘씨	신규한 퀴놀론 유도체 및 그의 제조 방법
GB2289674A (en)	1994-05-23	1995-11-29	Pfizer	Antibacterial naphthyridine
DE4435479A1 (de)	1994-10-04	1996-04-11	Bayer Ag	Chinolon- und Naphthyridoncarbonsäure-Derivate
DE19546249A1 (de) *	1995-12-12	1997-06-19	Bayer Ag	Neue Kristallmodifikation des 1-Cyclopropyl-7-([S,S]-2,8-diazabicyclo[4,3,0]non-8-yl)-6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäure Hydrochlorid (CDCH), Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen
AU713704B2 (en) *	1996-01-31	1999-12-09	Sankyo Company Limited	Agents for the treatment and prevention of aids

1997
- 1997-11-24 DE DE19751948A patent/DE19751948A1/de not_active Withdrawn
1998
- 1998-11-12 RU RU2000116546/04A patent/RU2219175C2/ru active
- 1998-11-12 AU AU15619/99A patent/AU732977B2/en not_active Expired
- 1998-11-12 EE EEP200000241A patent/EE04281B1/xx unknown
- 1998-11-12 BR BRPI9814894 patent/BRPI9814894B8/pt not_active IP Right Cessation
- 1998-11-12 AT AT98959874T patent/ATE294169T1/de active
- 1998-11-12 DK DK98959874T patent/DK1034173T3/da active
- 1998-11-12 ES ES98959874T patent/ES2241185T3/es not_active Expired - Lifetime
- 1998-11-12 ID IDW20000981A patent/ID26840A/id unknown
- 1998-11-12 CA CA2711645A patent/CA2711645C/en not_active Expired - Lifetime
- 1998-11-12 SK SK748-2000A patent/SK285492B6/sk not_active IP Right Cessation
- 1998-11-12 KR KR1020007005597A patent/KR100589549B1/ko not_active IP Right Cessation
- 1998-11-12 PT PT98959874T patent/PT1034173E/pt unknown
- 1998-11-12 IL IL13586698A patent/IL135866A0/xx not_active IP Right Cessation
- 1998-11-12 WO PCT/EP1998/007237 patent/WO1999026940A2/de active IP Right Grant
- 1998-11-12 CZ CZ20001926A patent/CZ297212B6/cs not_active IP Right Cessation
- 1998-11-12 DE DE59812758T patent/DE59812758D1/de not_active Expired - Lifetime
- 1998-11-12 EP EP98959874A patent/EP1034173B1/de not_active Expired - Lifetime
- 1998-11-12 CN CNB988114445A patent/CN1151151C/zh not_active Expired - Lifetime
- 1998-11-12 HU HU0004337A patent/HU228337B1/hu active Protection Beyond IP Right Term
- 1998-11-12 TR TR2000/01472T patent/TR200001472T2/xx unknown
- 1998-11-12 SI SI9830772T patent/SI1034173T1/xx unknown
- 1998-11-12 PL PL341088A patent/PL192461B1/pl unknown
- 1998-11-12 JP JP2000522098A patent/JP4445667B2/ja not_active Expired - Lifetime
- 1998-11-12 NZ NZ504657A patent/NZ504657A/en not_active IP Right Cessation
- 1998-11-12 CA CA2311540A patent/CA2311540C/en not_active Expired - Lifetime
- 1998-11-18 IN IN3456DE1998 patent/IN189753B/en unknown
- 1998-11-20 MY MYPI98005283A patent/MY129324A/en unknown
- 1998-11-23 TW TW087119353A patent/TW513427B/zh not_active IP Right Cessation
- 1998-11-23 ZA ZA9810669A patent/ZA9810669B/xx unknown
- 1998-11-23 PE PE1998001139A patent/PE20000007A1/es not_active IP Right Cessation
- 1998-11-24 AR ARP980105947A patent/AR016694A1/es active IP Right Grant
- 1998-11-24 SV SV1998000139A patent/SV1998000139A/es not_active Application Discontinuation
- 1998-11-24 UY UY25265A patent/UY25265A1/es unknown
- 1998-11-24 HN HN1998000179A patent/HN1998000179A/es unknown
- 1998-11-24 CO CO98069225A patent/CO5011069A1/es unknown
- 1998-12-11 UA UA2000063686A patent/UA56286C2/uk unknown
2000
- 2000-05-22 BG BG104467A patent/BG64532B1/bg unknown
- 2000-05-23 HR HR20000332A patent/HRP20000332B1/xx not_active IP Right Cessation
- 2000-05-23 NO NO20002637A patent/NO315748B1/no not_active IP Right Cessation
- 2000-05-24 CU CU20000115A patent/CU22953A3/es unknown
2001
- 2001-07-03 HK HK01104581A patent/HK1034080A1/xx not_active IP Right Cessation
2002
- 2002-09-04 CN CNB021319626A patent/CN1200938C/zh not_active Expired - Lifetime
2003
- 2003-04-03 US US10/406,129 patent/US6897315B2/en not_active Expired - Lifetime
- 2003-11-18 HK HK03108394A patent/HK1056169A1/xx not_active IP Right Cessation
2005
- 2005-05-11 US US11/127,811 patent/US7115744B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
UA56286C2 (uk)	2003-05-15
HRP20000332A2 (en)	2001-04-30
AU732977B2 (en)	2001-05-03
SI1034173T1 (en)	2005-10-31
AR016694A1 (es)	2001-07-25
NO315748B1 (no)	2003-10-20
TW513427B (en)	2002-12-11
US20050209276A1 (en)	2005-09-22
US20030208069A1 (en)	2003-11-06
SK7482000A3 (en)	2000-10-09
NZ504657A (en)	2001-04-27
CN1200938C (zh)	2005-05-11
CA2311540C (en)	2011-06-14
CN1279683A (zh)	2001-01-10
CA2711645A1 (en)	1999-06-03
BRPI9814894B1 (pt)	2011-10-18
SK285492B6 (sk)	2007-02-01
AU1561999A (en)	1999-06-15
WO1999026940A3 (de)	1999-08-12
ID26840A (id)	2001-02-15
CU22953A3 (es)	2004-06-21
UY25265A1 (es)	1999-07-19
HUP0004337A3 (en)	2004-07-28
MY129324A (en)	2007-03-30
PL341088A1 (en)	2001-03-26
ZA9810669B (en)	1999-05-26
CZ297212B6 (cs)	2006-10-11
BG104467A (en)	2001-08-31
US6897315B2 (en)	2005-05-24
EP1034173A2 (de)	2000-09-13
DK1034173T3 (da)	2005-07-25
IN189753B (ko)	2003-04-19
DE19751948A1 (de)	1999-05-27
CN1418879A (zh)	2003-05-21
CA2711645C (en)	2016-04-26
HRP20000332B1 (en)	2009-01-31
PL192461B1 (pl)	2006-10-31
ATE294169T1 (de)	2005-05-15
CA2311540A1 (en)	1999-06-03
CO5011069A1 (es)	2001-02-28
KR100589549B1 (ko)	2006-06-14
TR200001472T2 (tr)	2002-06-21
NO20002637L (no)	2000-05-23
HN1998000179A (es)	1999-02-09
SV1998000139A (es)	1999-04-13
CZ20001926A3 (cs)	2000-11-15
HK1034080A1 (en)	2001-10-12
PT1034173E (pt)	2005-08-31
HUP0004337A2 (hu)	2001-10-28
BRPI9814894B8 (pt)	2021-07-06
JP4445667B2 (ja)	2010-04-07
US7115744B2 (en)	2006-10-03
JP2001524477A (ja)	2001-12-04
NO20002637D0 (no)	2000-05-23
PE20000007A1 (es)	2000-03-05
BG64532B1 (bg)	2005-06-30
HK1056169A1 (en)	2004-02-06
HU228337B1 (en)	2013-03-28
ES2241185T3 (es)	2005-10-16
DE59812758D1 (de)	2005-06-02
CN1151151C (zh)	2004-05-26
WO1999026940A2 (de)	1999-06-03
RU2219175C2 (ru)	2003-12-20
EE04281B1 (et)	2004-04-15
EE200000241A (et)	2001-06-15
IL135866A0 (en)	2001-05-20
KR20010032361A (ko)	2001-04-16
BRPI9814894A (pt)	2000-10-03

Publication	Publication Date	Title
EP1034173B1 (de)	2005-04-27	Verfahren zur herstellung von 8-methoxy-chinoloncarbonsäuren
EP0049355B1 (de)	1984-10-10	7-Amino-1-cyclopropyl-4-oxo-1,4-dihydro-(naphthyridin oder chinolin)-3-carbonsäuren, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel
DE60312701T2 (de)	2007-12-06	Darstellung von 1h-imidazoä4,5-cüchinolin-4-aminen über neue 1h-imidazoä4,5-cüchinolin-4-cyano- und 1h-imidazoä4,5-cüchinolin-4-carboxamid intermediate
DE69928792T2 (de)	2006-07-20	Imidazo-pyridin verbindungen, die die sekretion von magensäure hemmen
DE3514076C2 (ko)	1989-03-30
DE69805787T2 (de)	2003-01-02	Verbindungen zur hemmung der magensäuresekretion
DE69430950T2 (de)	2002-11-14	Chinolonderivate und verfahren zu deren herstellung
EP0299470A1 (de)	1989-01-18	Imidazo[1,2-a]pyridine
EP0656353A1 (de)	1995-06-07	Aminochinolin-Derivate mit einer Wirksamkeit gegen Malariaerreger
DD244553A5 (de)	1987-04-08	Verfahren zur herstellung von 5,6-difluor-naphthyridinen und 5,6,8-trifluorchinolinen
DE2720085C2 (ko)	1988-11-17
EP0387821B1 (de)	1994-08-24	2-Alkyl-4-arylmethylaminochinoline, ihre Verwendung und daraus hergestellte Arzneimittel
EP0216345A2 (de)	1987-04-01	Chinolinderivate
DE3418271A1 (de)	1985-11-21	Neue benzazepinderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
AU2003205733B8 (en)	2008-09-04	R-(-)-1-[2-(7-chlorobenzo [b] thiophen-3 - yl - methoxy) -2-(2,4-dichlorophenyl)-ethyl] -1H-imidazole
DE3880953T2 (de)	1993-10-14	Chinolinderivate, Verfahren zur Herstellung davon und diese enthaltendes antibakterielles Mittel.
DE3326724A1 (de)	1985-02-07	In 1-stellung substituierte 4-hydroxymethyl-pyrrolidinone, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen und zwischenprodukte
DE3639465A1 (de)	1988-05-19	Optisch aktive gyrasehemmer, ihre herstellung und verwendung als antibiotika
DD298402A5 (de)	1992-02-20	Substituierte isothiazolo-pyridon-azetidinylderivate, ihre herstellung und ihre anwendung als medikament
EP0665228A1 (de)	1995-08-02	Neue 3-Phenylsulfonyl-3,7-diazabicyclo(3,3,1)nonan-Verbindungen enthaltende Arzneimittel
DE68915928T2 (de)	1994-09-22	Benzoheterozyklische Verbindungen.
DE3852442T2 (de)	1995-04-27	7-(2-Methyl-4-aminopyrrolidinyl)naphthyridin und Chenolin-Verbindungen.
EP0647644B1 (de)	1997-11-05	Aktibakteriell wirksame Pyrido 1,2,3-d,e 1,3,4 Benzoxadiazinderivate
EP0290003A2 (de)	1988-11-09	Neue Imidazole
DE60037587T2 (de)	2008-04-30	Optisch aktive quinolin-carbonsäure-derivate mit einem 7-pyrrolidin-substituenten, der die optische aktivität verursacht und ein verfahren zu seiner herstellung

Legal Events

Date	Code	Title	Description
2000-07-28	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2000-09-13	17P	Request for examination filed	Effective date: 20000626
2000-09-13	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2000-09-13	AX	Request for extension of the european patent	Free format text: LT PAYMENT 20000626;LV PAYMENT 20000626;RO PAYMENT 20000626;SI PAYMENT 20000626
2002-04-17	17Q	First examination report despatched	Effective date: 20020227
2004-01-07	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: BAYER HEALTHCARE AG
2004-10-08	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2005-03-04	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2005-03-11	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2005-04-27	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2005-04-27	AX	Request for extension of the european patent	Extension state: LT LV RO SI
2005-04-27	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH
2005-04-29	REG	Reference to a national code	Ref country code: CH Ref legal event code: NV Representative=s name: E. BLUM & CO. PATENTANWAELTE Ref country code: CH Ref legal event code: EP
2005-05-18	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D Free format text: LANGUAGE OF EP DOCUMENT: GERMAN
2005-06-02	REF	Corresponds to:	Ref document number: 59812758 Country of ref document: DE Date of ref document: 20050602 Kind code of ref document: P
2005-07-12	REG	Reference to a national code	Ref country code: SE Ref legal event code: TRGR Ref country code: GR Ref legal event code: EP Ref document number: 20050401948 Country of ref document: GR
2005-07-25	REG	Reference to a national code	Ref country code: DK Ref legal event code: T3
2005-08-31	REG	Reference to a national code	Ref country code: PT Ref legal event code: SC4A Effective date: 20050708
2005-09-07	GBT	Gb: translation of ep patent filed (gb section 77(6)(a)/1977)	Effective date: 20050817
2005-10-16	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2241185 Country of ref document: ES Kind code of ref document: T3
2006-03-03	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2006-03-03	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2006-03-17	ET	Fr: translation filed
2006-04-19	26N	No opposition filed	Effective date: 20060130
2007-10-30	REG	Reference to a national code	Ref country code: CH Ref legal event code: PFA Owner name: BAYER HEALTHCARE AG Free format text: BAYER HEALTHCARE AG# #51368 LEVERKUSEN (DE) -TRANSFER TO- BAYER HEALTHCARE AG# #51368 LEVERKUSEN (DE)
2009-04-09	REG	Reference to a national code	Ref country code: PT Ref legal event code: PC4A Owner name: BAYER SCHERING PHARMA AG, DE Effective date: 20090311
2009-04-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: PUE Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT Free format text: BAYER HEALTHCARE AG# #51368 LEVERKUSEN (DE) -TRANSFER TO- BAYER SCHERING PHARMA AKTIENGESELLSCHAFT#MUELLERSTRASSE 178#13353 BERLIN (DE)
2009-10-30	REG	Reference to a national code	Ref country code: SI Ref legal event code: SP73 Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT; DE Effective date: 20090723
2009-12-01	NLS	Nl: assignments of ep-patents	Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT Effective date: 20090918
2010-01-08	REG	Reference to a national code	Ref country code: FR Ref legal event code: TP
2012-08-02	REG	Reference to a national code	Ref country code: DE Ref legal event code: R081 Ref document number: 59812758 Country of ref document: DE Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE Free format text: FORMER OWNER: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, 13353 BERLIN, DE Effective date: 20120612
2012-11-30	REG	Reference to a national code	Ref country code: CH Ref legal event code: PUE Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE Free format text: FORMER OWNER: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE
2013-02-28	BECH	Be: change of holder	Owner name: BAYER INTELLECTUAL PROPERTY G.M.B.H. Effective date: 20130211
2013-03-01	REG	Reference to a national code	Ref country code: FR Ref legal event code: TP Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE Effective date: 20130130 Ref country code: FR Ref legal event code: CD Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE Effective date: 20130130
2013-04-02	REG	Reference to a national code	Ref country code: ES Ref legal event code: PC2A Owner name: BAYER INTELLECTUAL PROPERTY GMBH Effective date: 20130319
2013-05-29	REG	Reference to a national code	Ref country code: DE Ref legal event code: R081 Ref document number: 59812758 Country of ref document: DE Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE Free format text: FORMER OWNER: BAYER PHARMA AKTIENGESELLSCHAFT, 13353 BERLIN, DE Effective date: 20130410
2013-07-03	REG	Reference to a national code	Ref country code: NL Ref legal event code: TD Effective date: 20130625 Ref country code: NL Ref legal event code: SD Effective date: 20130625
2014-01-08	REG	Reference to a national code	Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20131212 AND 20131218
2014-02-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: PC Ref document number: 294169 Country of ref document: AT Kind code of ref document: T Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE Effective date: 20131218
2015-10-23	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 18
2016-10-28	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 19
2017-10-26	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 20
2017-12-29	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: LU Payment date: 20171024 Year of fee payment: 20
2018-01-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DK Payment date: 20171110 Year of fee payment: 20 Ref country code: DE Payment date: 20171108 Year of fee payment: 20 Ref country code: FR Payment date: 20171026 Year of fee payment: 20 Ref country code: FI Payment date: 20171109 Year of fee payment: 20 Ref country code: MC Payment date: 20171129 Year of fee payment: 20
2018-02-28	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: SE Payment date: 20171113 Year of fee payment: 20 Ref country code: PT Payment date: 20171102 Year of fee payment: 20 Ref country code: NL Payment date: 20171031 Year of fee payment: 20 Ref country code: IT Payment date: 20171123 Year of fee payment: 20 Ref country code: AT Payment date: 20171026 Year of fee payment: 20 Ref country code: GB Payment date: 20171108 Year of fee payment: 20 Ref country code: CH Payment date: 20171114 Year of fee payment: 20 Ref country code: ES Payment date: 20171201 Year of fee payment: 20 Ref country code: IE Payment date: 20171109 Year of fee payment: 20 Ref country code: GR Payment date: 20171025 Year of fee payment: 20 Ref country code: BE Payment date: 20171024 Year of fee payment: 20
2018-04-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: CY Payment date: 20171109 Year of fee payment: 20
2018-11-12	REG	Reference to a national code	Ref country code: DE Ref legal event code: R071 Ref document number: 59812758 Country of ref document: DE
2018-11-14	REG	Reference to a national code	Ref country code: NL Ref legal event code: MK Effective date: 20181111
2018-11-19	REG	Reference to a national code	Ref country code: DK Ref legal event code: EUP Effective date: 20181112
2018-11-30	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2018-12-05	REG	Reference to a national code	Ref country code: GB Ref legal event code: PE20 Expiry date: 20181111
2018-12-13	REG	Reference to a national code	Ref country code: BE Ref legal event code: MK Effective date: 20181112
2018-12-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MK07 Ref document number: 294169 Country of ref document: AT Kind code of ref document: T Effective date: 20181112
2018-12-26	REG	Reference to a national code	Ref country code: IE Ref legal event code: MK9A
2019-01-02	REG	Reference to a national code	Ref country code: SE Ref legal event code: EUG
2019-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20181112 Ref country code: PT Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20181119
2019-02-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20181111
2020-08-03	REG	Reference to a national code	Ref country code: ES Ref legal event code: FD2A Effective date: 20200803
2020-10-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20181113